PCIB PCI Biotech Holding ASA

PCI Biotech: Minutes from Annual General Meeting 2020

PCI Biotech: Minutes from Annual General Meeting 2020

Oslo, 27 May 2020. The Annual General Meeting in PCI Biotech Holding ASA took place today, 27 May 2020.

All proposals were resolved by the Annual General Meeting as presented in the notice convening the general meeting distributed on 6 May 2020.

The complete minutes of the Annual General Meeting are attached to this release and are available on

Contact information:    

PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo          

Ronny Skuggedal, CFO, , Mobile:

This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Attachment

EN
27/05/2020

Underlying

PCIBPCI Biotech Holding ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PCI Biotech Holding ASA

 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech: Minutes of Annual General Meeting 2025

PCI Biotech: Minutes of Annual General Meeting 2025 Oslo, 22 May 2025. The Annual General Meeting in PCI Biotech Holding ASA took place today, 22 May 2025.  All the matters on the agenda were approved and the minutes of the Annual General Meeting are attached to this release and are available on Contact information:        PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo        Ronny Skuggedal, CEO / CFO, , Mobile: This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act.  Attachment ...

May 22, 2025 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI BIotech: Disclosure of voting rights for Chair of the Board

PCI BIotech: Disclosure of voting rights for Chair of the Board Oslo, 20 May 2025. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of Hans Peter Bøhn, Chair of the Board of Directors. Hans Peter Bøhn is chair of PCI Biotech’s board of directors and shall open the annual general meeting of the Company on 22 May 2025. Mr. Bøhn holds 123,662 shares, representing 0.3 percent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 3,957,330 additional shares. In total, Mr. Bøhn will represent and vote for...

May 20, 2025 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

Notice of Annual General Meeting 2025

Notice of Annual General Meeting 2025 Oslo, Norway, 30 April 2025 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park on 22 May 2025 at 10:00am (CEST). The notice and proposed resolutions to the annual general meeting are attached. The notice, including all appendices, will be made available at PCI Biotech's corporate website . For further information, please contact: Ronny Skuggedal, CEO/CFO, E-mail: Office: Mobile: This information is subject to the disclosure requirements pursuant to section 5-12 of t...

April 30, 2025 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech Holding ASA: Annual Report 2024

PCI Biotech Holding ASA: Annual Report 2024 Oslo, Norway, April 24, 2025The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2024. Please find the report attached, as well as the report according to the European Single Electronic Format (ESEF). The Annual Report 2024 is also available on the company’s website For further information, please contact:        PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo                Ronny Skuggedal, CEO, , Mobile:  757 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwe...

April 24, 2025 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech full year 2024 interim results

PCI Biotech full year 2024 interim results Oslo (Norway), 27 February 2025 – PCI Biotech (OSE: PCIB), today announces its preliminary full year 2024 results. Please find enclosed the interim report and presentation. Highlights review OperationsPCI Biotech’s 2024 development goals were to demonstrate scalability and manufacturing process benefits of the photochemical-based technology (PCL) in viral vector (AAV) manufacturing by advancing the technology into mini benchtop bioreactors, which are considered representative for commercial manufacturing. Recent mini benchtop bioreactor results...

February 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch